Perceive Biotherapeutics is a clinical stage company developing novel drugs and gene therapies for ocular diseases.
Perceive’s lead program for age-related macular degeneration (AMD) is a gene therapy delivering an engineered, protective complement factor transgene to genetically defined patients at risk of developing both dry and wet AMD. Perceive’s second program is a neuroprotective gene therapy aimed at slowing vision loss in a variety of disease instances, with the primary indication being glaucoma. Catalio Venture Partner Eugene De Juan is the company’s CSO.
Total raised: $78M
Investors 2
| Date | Name | Website |
| 03.06.2022 | Johns Hopk... | ventures.j... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.01.2023 | Series B | $78M | Johnson &a... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 09.01.2023 | Perceive Biotherapeutics raises USD 78 million in Series B i... | RALEIGH, North Carolina, Jan. 6, 2023 — The RD Fund (Retinal Degeneration Fund), the Foundation Figh... | vcbay.news... |
| 06.01.2023 | Biotech startup Perceive Bio closes $78M in Series B funding... | TL;DR Perceive Biotherapeutics, a Silicon Valley biotech tech startup focused on technologies and th... | techstartu... |
| 06.01.2023 | Perceive Biotherapeutics Closes $78M in Series B Funding | Perceive Biotherapeutics, a San Francisco, CA-based biotech company focused on technologies and ther... | finsmes.co... |
| 05.01.2023 | Perceive Biotherapeutics Grabs $78M Series B | SOUTH SAN FRANCISCO, CA, Perceive Biotherapeutics today announced the closing of a $78 million Ser... | vcnewsdail... |
| - | Perceive Biotherapeutics | - | fastfounde... |